Oasmia Pharmaceuticals has appointed Dr Ulf Jungnelius as its new senior medical advisor.
He brings over 40 years of experience in oncology clinical research and development to the Uppsala, Sweden-based firm, having held leading positions in oncology at Eli Lilly, Pfizer and Takeda.
Most recently, Dr Jungnelius served as vice president, CR&D oncology at Celgene and continues serve as a partner for Healthcom, a healthcare technology company based in the US.
Julian Aleksov, executive chairman of Oasmia, said: “We are thrilled to add Dr Ulf Jungnelius, an individual with a very strong therapeutic area expertise and who has been a key driver in taking oncology blockbusters to regulatory approval and commercial success, to the Oasmia Pharmaceutical team.”
Meanwhile, Oasmia also announced Anders Lundin’s resignation as chief financial officer.
Lundin joined the oncology drug developer in 2014, having previously served as head of finance at Galderma, a Swiss dermatology firm.
He will leave the company to pursue other business opportunities on 31 March.